- $9.53bn
- $10.38bn
- $2.09bn
Deals of the day-Mergers and acquisitions
Press Digest: Financial Times - October 22
Brief: Qiagen And Eqt Private Equity Announce Agreement On A Recommended Voluntary All-Cash Public Takeover Offer
EQT to buy molecular testing firm Qiagen for $10.8 billion (updated)
Buyout firm EQT to acquire Qiagen for $10.8 billion
Netherlands' Qiagen agrees EUR 10.8 bln EQT buyout; suspends FY 2026 outlook
EQT in advanced talks to buy testing firm Qiagen, Bloomberg News reports (updated)
EQT in advanced talks to buy testing firm Qiagen, Bloomberg News reports
Brief: Eqt Is In Advanced Talks To Buy Testing Firm Qiagen- Bloomberg News
Qiagen gains 4% after report of fresh private equity interest
Delaware jury finds Parse infringed three genetic-sequencing patents (updated)
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
Brief: 10X Genomics Wins Patent Infringement Verdict Against Parse Biosciences
Qiagen names Filtration Group's Pratt as CEO; shares down
Brief: Qiagen Appoints Jonathan M. Pratt As CEO
Netherlands' Qiagen Q2 sales flat, exceed company outlook
Brief: Qiagen NV Q2 Adjusted EPS USD 0.62
Brief: Qiagen Highlights Molecular Testing Solutions Supporting Response To Growing U.S. Cyclospora Outbreak
EQT, Advent, KKR explore takeover of diagnostics firm Qiagen, Bloomberg News reports (updated)